Suchergebnisse - "KESKİNKILIÇ, Merve"

Author Correction: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Autoren: Özyurt, Neslihan Alkan, Ali Gülbağcı, Burcu et al.

Quelle: Scientific Reports ; volume 15, issue 1 ; ISSN 2045-2322

Verfügbarkeit: https://doi.org/10.1038/s41598-024-80587-9
https://www.nature.com/articles/s41598-024-80587-9.pdf
https://www.nature.com/articles/s41598-024-80587-9

Comparison of Prognostic Risk Models (IMDC, MSKCC, CFF) in Patients Diagnosed with Metastatic Renal Cell Cancer.

Alternate Title: Metastatik Renal Hücreli Kanser Tanılı Hastalarda Prognostik Risk Modellerinin (IMDC, MSKCC, CCF) Karşılaştırılması. (Turkish)

Autoren: KESKİNKILIÇ, Merve CANASLAN, Kübra SEMİZ, Hüseyin Salih et al.

Quelle: Forbes Journal of Medicine; Aug2025, Vol. 6 Issue 2, p180-187, 8p

Schlagwörter: RISK assessment, STATISTICAL correlation, PREDICTION models, ACADEMIC medical centers, T-test (Statistics), IMMUNOTHERAPY, FISHER exact test, MULTIPLE regression analysis, CANCER patients, RETROSPECTIVE studies, DESCRIPTIVE statistics, MANN Whitney U Test, CHI-squared test, METASTASIS, KAPLAN-Meier estimator, LOG-rank test, RENAL cell carcinoma, RESEARCH, MEDICAL records, ACQUISITION of data, COMPARATIVE studies, PROGRESSION-free survival, CONFIDENCE intervals, DATA analysis software, OVERALL survival, TIME, PROPORTIONAL hazards models, EVALUATION, DISEASE risk factors

Geografische Kategorien: TURKEY

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Autoren: Ozkanli, Gulhan Duman, Berna Bozkurt Aydin, Dincer et al.

Schlagwörter: CDK 4, 6 inhibitors, HER2-negative metastatic breast cancer, HR-positive, letrozole

Relation: Future Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/51149; WOS:000991646700001

Verfügbarkeit: https://hdl.handle.net/11499/51149
https://doi.org/10.2217/fon-2022-1287

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Autoren: Kalender, Mehmet Emin Hacıbekiroğlu, İlhan Doğan, Mutlu et al.

Verfügbarkeit: https://doi.org/10.1186/s12885-023-10609-8
https://avesis.kocaeli.edu.tr/publication/details/78fc1821-e830-4912-a671-d972cab74a97/oai

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023) ; Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC Cancer, (2023), 23, 1, (136), 10.1186/s12885-023-10609-8)

Autoren: Karacin, Cengiz Öksüzoğlu, Berna Demirci, Ayşe et al.

Schlagwörter: CDK 4/6 Inhibitor Therapy, Breast Cancer, Disease Progression

Dateibeschreibung: application/pdf

Relation: BMC Cancer; Diğer; https://hdl.handle.net/20.500.12511/10700; 23; Q2; 000941147400001

Verfügbarkeit: https://hdl.handle.net/20.500.12511/10700
https://doi.org/10.1186/s12885-023-10662-3

Association Angiotensin Converting Enzyme-2 with Lung Cancer.

Alternate Title: Akciğer Kanseri ve Anjiotensin Dönüştürücü Enzim-2 İlişkisi. (Turkish)

Autoren: ERTUĞRUL, Ayşe Vasfiye ÖMEROĞLU ŞİMŞEK, Gökçen AKTAŞ, Tekincan et al.

Quelle: Izmir Katip Celebi University Faculty of Health Sciences Journal / İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi; oca2024, Vol. 9 Issue 1, p81-86, 6p

Schlagwörter: ANGIOTENSIN converting enzyme, SQUAMOUS cell carcinoma, ADENOCARCINOMA, LUNG cancer, LUNG tumors, MICROSCOPES, BIOMARKERS, OVERALL survival

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Autoren: Hizal, Mutlu Bilgin, Burak Paksoy, Nail et al.

Schlagwörter: alectinib, ALK, first-line, non-small-cell lung cancer, real-world

Relation: Future Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11616/100780; 18; 23; 2573; 2582; Q1; WOS:000814515100001; Q3

Verfügbarkeit: https://hdl.handle.net/11616/100780
https://doi.org/10.2217/fon-2022-0083

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Weitere Verfasser: Yumuk, Perran Fulden Hızal, Mutlu Bilgin, Burak et al.

Quelle: Journal of Cancer Research and Clinical Oncology

Schlagwörter: Oncology, Alectinib, Percentage of ALK-positive cells, Break-apart, Predictive, Response

Dateibeschreibung: pdf

Relation: Author's final manuscript; Koç University Institutional Repository; IR04197; WoS; Scopus; PubMed; NA; http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/11073

Verfügbarkeit: https://doi.org/10.1007/s00432-022-04252-2
http://libdigitalcollections.ku.edu.tr/cdm/ref/collection/IR/id/11073